{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:42:25Z","timestamp":1790948545751,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T00:00:00Z","timestamp":1532304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T00:00:00Z","timestamp":1532304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5dione) is a polyphenol extracted from turmeric that has long been advocated for the treatment of a variety of conditions including neurodegenerative and inflammatory disorders. Despite this promise, the clinical use of curcumin has been limited by the poor solubility and low bioavailability of this molecule. In this article, we describe a novel nanocarrier formulation comprising Pluronic-F127 stabilised D-\u03b1-Tocopherol polyethene glycol 1000 succinate nanoparticles, which were used to successfully solubilize high concentrations (4.3\u2009mg\/mL) of curcumin. Characterisation with x-ray diffraction and<jats:italic>in vitro<\/jats:italic>release assays localise curcumin to the nanocarrier interior, with each particle measuring &lt;20\u2009nm diameter. Curcumin-loaded nanocarriers (CN) were found to significantly protect against cobalt chloride induced hypoxia and glutamate induced toxicity<jats:italic>in vitro<\/jats:italic>, with CN treatment significantly increasing R28 cell viability. Using established glaucoma-related<jats:italic>in vivo<\/jats:italic>models of ocular hypertension (OHT) and partial optic nerve transection (pONT), topical application of CN twice-daily for three weeks significantly reduced retinal ganglion cell loss compared to controls. Collectively, these results suggest that our novel topical CN formulation has potential as an effective neuroprotective therapy in glaucoma and other eye diseases with neuronal pathology.<\/jats:p>","DOI":"10.1038\/s41598-018-29393-8","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T10:10:45Z","timestamp":1531822245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-1635","authenticated-orcid":false,"given":"Benjamin M.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Pahlitzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiama","family":"Balendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Malaguarnera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehtesham","family":"Shamsher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Hamze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdinasir","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Acom","family":"Sornsute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-4610","authenticated-orcid":false,"given":"Satyanarayana","family":"Somavarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Francesca","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,23]]},"reference":[{"key":"29393_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"1e21","author":"YCC Tham","year":"2014","unstructured":"Tham, Y. C. C. et al. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040. A Systematic Review and Meta-Analysis. Ophthalmology 1e21, 2081\u20132090 (2014).","journal-title":"Ophthalmology"},{"key":"29393_CR2","doi-asserted-by":"publisher","unstructured":"Davis, B. M., Crawley, L., Pahlitzsch, M., Javaid, F. & Cordeiro, M. F. Glaucoma: the retina and beyond. Acta Neuropathol. 807\u2013826 https:\/\/doi.org\/10.1007\/s00401-016-1609-2 (2016).","DOI":"10.1007\/s00401-016-1609-2"},{"key":"29393_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ophtha.2007.03.017","volume":"115","author":"MC Leske","year":"2008","unstructured":"Leske, M. C., Wu, S. Y., Hennis, A., Honkanen, R. & Nemesure, B. Risk Factors for Incident Open-angle Glaucoma. The Barbados Eye Studies. Ophthalmology 115, 85\u201393 (2008).","journal-title":"Ophthalmology"},{"key":"29393_CR4","doi-asserted-by":"crossref","unstructured":"Collaborative Normal-Tension Glaucoma Study, Anderson, D. R., Drance, S. M. & Schulzer, M. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126, 487\u201397 (1998).","DOI":"10.1016\/S0002-9394(98)00223-2"},{"key":"29393_CR5","first-page":"2109","volume":"9","author":"K Tian","year":"2015","unstructured":"Tian, K. et al. Current perspective of neuroprotection and glaucoma. Clin. Ophthalmol. 9, 2109\u201318 (2015).","journal-title":"Clin. Ophthalmol."},{"key":"29393_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00055735-200204000-00002","volume":"13","author":"FB Wein","year":"2002","unstructured":"Wein, F. B. & Levin, L. A. Current understanding of neuroprotection in glaucoma. Curr. Opin. Ophthalmol. 13, 61\u20137 (2002).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"29393_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1517\/13543784.6.8.1063","volume":"6","author":"LB Cantor","year":"1997","unstructured":"Cantor, L. B. & Burke, J. Brimonidine. Expert Opin. Investig. Drugs 6, 1063\u20131083 (1997).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"29393_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","volume":"127","author":"M Saylor","year":"2009","unstructured":"Saylor, M., McLoon, L. K., Harrison, A. R. & Lee, M. S. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch. Ophthalmol. (Chicago, Ill. 1960) 127, 402\u20136 (2009).","journal-title":"Arch. Ophthalmol. (Chicago, Ill. 1960)"},{"key":"29393_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/jop.2005.21.475","volume":"21","author":"J-C Tsai","year":"2005","unstructured":"Tsai, J.-C. & Chang, H.-W. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. J. Ocul. Pharmacol. Ther. 21, 475\u201382 (2005).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"29393_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2006-960004","volume":"57","author":"HP Ammon","year":"1991","unstructured":"Ammon, H. P. & Wahl, M. A. Pharmacology of Curcuma longa. Planta Med. 57, 1\u20137 (1991).","journal-title":"Planta Med."},{"key":"29393_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/157488912803252032","volume":"7","author":"DSHL Kim","year":"2012","unstructured":"Kim, D. S. H. L., Kim, J. Y. & Han, Y. Curcuminoids in neurodegenerative diseases. Recent Pat. CNS Drug Discov. 7, 184\u2013204 (2012).","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"29393_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.coph.2012.09.008","volume":"13","author":"V Chrysostomou","year":"2013","unstructured":"Chrysostomou, V., Rezania, F., Trounce, I. A. & Crowston, J. G. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr. Opin. Pharmacol. 13, 12\u201315 (2013).","journal-title":"Curr. Opin. Pharmacol."},{"key":"29393_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/jnc.12325","volume":"127","author":"N Himori","year":"2013","unstructured":"Himori, N. et al. Critical role of Nrf2 in oxidative stress-induced retinal ganglion cell death. J. Neurochem. 127, 669\u201380 (2013).","journal-title":"J. Neurochem."},{"key":"29393_CR14","doi-asserted-by":"publisher","first-page":"e68935","DOI":"10.1371\/journal.pone.0068935","volume":"8","author":"J Zhu","year":"2013","unstructured":"Zhu, J. et al. The Role of Peroxisome Proliferator-Activated Receptor and Effects of Its Agonist, Pioglitazone, on a Rat Model of Optic Nerve Crush: PPAR\u03b3 in Retinal Neuroprotection. PLoS One 8, e68935 (2013).","journal-title":"PLoS One"},{"key":"29393_CR15","first-page":"2616","volume":"42","author":"C Maih\u00f6fner","year":"2001","unstructured":"Maih\u00f6fner, C. et al. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest. Ophthalmol. Vis. Sci. 42, 2616\u201324 (2001).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"29393_CR16","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1167\/iovs.10-5873","volume":"52","author":"Y Dai","year":"2011","unstructured":"Dai, Y. et al. Inducible nitric oxide synthase-mediated alteration of mitochondrial OPA1 expression in ocular hypertensive rats. Invest. Ophthalmol. Vis. Sci. 52, 2468\u201376 (2011).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"29393_CR17","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s12035-014-8945-9","volume":"52","author":"M Wong","year":"2015","unstructured":"Wong, M. et al. Therapeutic Retrobulbar Inhibition of STAT3 Protects Ischemic Retina Ganglion Cells. Mol. Neurobiol. 52, 1364\u201377 (2015).","journal-title":"Mol. Neurobiol."},{"key":"29393_CR18","doi-asserted-by":"publisher","first-page":"13444","DOI":"10.1073\/pnas.0703707104","volume":"104","author":"L Guo","year":"2007","unstructured":"Guo, L. et al. Targeting amyloid-\u03b2 in glaucoma treatment. Proc Natl Acad Sci USA 104, 13444\u201313449 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"29393_CR19","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"CATT Group","year":"2011","unstructured":"CATT Group et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897\u20131908 (2011).","journal-title":"N. Engl. J. Med."},{"key":"29393_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ardp.201400266","volume":"347","author":"J Trujillo","year":"2014","unstructured":"Trujillo, J. et al. Mitochondria as a target in the therapeutic properties of curcumin. Arch. Pharm. (Weinheim). 347, 873\u201384 (2014).","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"29393_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3233\/JAD-2010-091336","volume":"20","author":"H-M Wang","year":"2010","unstructured":"Wang, H.-M. et al. PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J. Alzheimers. Dis. 20, 1189\u201399 (2010).","journal-title":"J. Alzheimers. Dis."},{"key":"29393_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/CJI.0b013e3182056ec4","volume":"34","author":"M-Y Song","year":"2011","unstructured":"Song, M.-Y. et al. Use of curcumin to decrease nitric oxide production during the induction of antitumor responses by IL-2. J. Immunother. 34, 149\u201364 (2011).","journal-title":"J. Immunother."},{"key":"29393_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep28956","volume":"6","author":"S Liu","year":"2016","unstructured":"Liu, S. et al. Curcumin ameliorates neuropathic pain by down-regulating spinal IL-1\u03b2 via suppressing astroglial NALP1 inflammasome and JAK2-STAT3 signalling. Sci. Rep. 6, 28956 (2016).","journal-title":"Sci. Rep."},{"key":"29393_CR24","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1074\/jbc.M404751200","volume":"280","author":"F Yang","year":"2005","unstructured":"Yang, F. et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892\u2013901 (2005).","journal-title":"J. Biol. Chem."},{"key":"29393_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3892\/ol.2014.2694","volume":"9","author":"J-Z Gao","year":"2015","unstructured":"Gao, J.-Z. et al. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma. Oncol. Lett. 9, 295\u2013299 (2015).","journal-title":"Oncol. Lett."},{"key":"29393_CR26","doi-asserted-by":"publisher","first-page":"e23194","DOI":"10.1371\/journal.pone.0023194","volume":"6","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. Curcumin Inhibits Neuronal and Vascular Degeneration in Retina after Ischemia and Reperfusion Injury. PLoS One 6, e23194 (2011).","journal-title":"PLoS One"},{"key":"29393_CR27","first-page":"1","volume":"0","author":"Y-K Yue","year":"2014","unstructured":"Yue, Y.-K. et al. Neuroprotective Effect of Curcumin Against Oxidative Damage in BV-2 Microglia and High Intraocular Pressure Animal Model. J. Ocul. Pharmacol. Ther. 0, 1\u20138 (2014).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"29393_CR28","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-04-0744","volume":"10","author":"RA Sharma","year":"2004","unstructured":"Sharma, R. A. et al. Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance. Clin. Cancer Res. 10, 6847\u20136854 (2004).","journal-title":"Clin. Cancer Res."},{"key":"29393_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0014-5793(03)01265-1","volume":"555","author":"Y Kaminaga","year":"2003","unstructured":"Kaminaga, Y. et al. Production of unnatural glucosides of curcumin with drastically enhanced water solubility by cell suspension cultures of Catharanthus roseus. FEBS Lett. 555, 311\u2013316 (2003).","journal-title":"FEBS Lett."},{"key":"29393_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","volume":"15","author":"S Gupta","year":"2013","unstructured":"Gupta, S., Patchva, S. & Aggarwal, B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 15, 195\u2013218 (2013).","journal-title":"AAPS J."},{"key":"29393_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1055\/s-2006-957450","volume":"64","author":"G Shoba","year":"1998","unstructured":"Shoba, G. et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64, 353\u20136 (1998).","journal-title":"Planta Med."},{"key":"29393_CR32","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1158\/1055-9965.EPI-07-2693","volume":"17","author":"SK Vareed","year":"2008","unstructured":"Vareed, S. K. et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev. 17, 1411\u20137 (2008).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"29393_CR33","first-page":"2895","volume":"21","author":"AL Cheng","year":"2001","unstructured":"Cheng, A. L. et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21, 2895\u2013900 (2001).","journal-title":"Anticancer Res."},{"key":"29393_CR34","first-page":"1894","volume":"7","author":"RA Sharma","year":"2001","unstructured":"Sharma, R. A. et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7, 1894\u2013900 (2001).","journal-title":"Clin. Cancer Res."},{"key":"29393_CR35","doi-asserted-by":"crossref","unstructured":"Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807\u201318","DOI":"10.1021\/mp700113r"},{"key":"29393_CR36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0090-9556(24)15211-7","volume":"27","author":"MH Pan","year":"1999","unstructured":"Pan, M. H., Huang, T. M. & Lin, J. K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27, 486\u201394 (1999).","journal-title":"Drug Metab. Dispos."},{"key":"29393_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/jop.1986.2.67","volume":"2","author":"VH Lee","year":"1986","unstructured":"Lee, V. H. & Robinson, J. R. Topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. 2, 67\u2013108 (1986).","journal-title":"J. Ocul. Pharmacol."},{"key":"29393_CR38","doi-asserted-by":"crossref","unstructured":"Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A. & Nair, S. Curcumin-Loaded Nanoparticles Potently Induce Adult Neurogenesis and Reverse Cognitive De fi cits in Alzheimer\u2019TMs Disease Model via Canonical Wnt\/\u03b2 -Catenin Pathway. 76\u2013103 (2014).","DOI":"10.1021\/nn405077y"},{"key":"29393_CR39","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1021\/jf202135j","volume":"59","author":"X Xie","year":"2011","unstructured":"Xie, X. et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J. Agric. Food Chem. 59, 9280\u20139 (2011).","journal-title":"J. Agric. Food Chem."},{"key":"29393_CR40","doi-asserted-by":"crossref","unstructured":"Cui, D., Chen, Y. & Wang, S. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. 3667\u20133677 (2012).","DOI":"10.2147\/IJN.S30428"},{"key":"29393_CR41","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.2147\/IJN.S30428","volume":"7","author":"W Wang","year":"2012","unstructured":"Wang, W. et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int. J. Nanomedicine 7, 3667\u201377 (2012).","journal-title":"Int. J. Nanomedicine"},{"key":"29393_CR42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.nano.2011.06.011","volume":"8","author":"YL Lin","year":"2012","unstructured":"Lin, Y. L. et al. A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells. Nanomedicine Nanotechnology, Biol. Med. 8, 318\u2013327 (2012).","journal-title":"Nanomedicine Nanotechnology, Biol. Med."},{"key":"29393_CR43","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.2147\/IJN.S38043","volume":"7","author":"C Li","year":"2012","unstructured":"Li, C. et al. Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin. Int. J. Nanomedicine 7, 5995\u20136002 (2012).","journal-title":"Int. J. Nanomedicine"},{"key":"29393_CR44","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/mt.2010.105","volume":"18","author":"D Sun","year":"2010","unstructured":"Sun, D. et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 18, 1606\u201314 (2010).","journal-title":"Mol. Ther."},{"key":"29393_CR45","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1096\/fj.13-235440","volume":"28","author":"J Galvao","year":"2014","unstructured":"Galvao, J. et al. Unexpected low-dose toxicity of the universal solvent DMSO. FASEB 28, 1317\u201330 (2014).","journal-title":"FASEB"},{"key":"29393_CR46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jep.2006.09.034","volume":"110","author":"B Kurien","year":"2007","unstructured":"Kurien, B. & Scofield, R. Curcumin\/turmeric solubilized in sodium hydroxide inhibits HNE protein modification\u2014An in vitro study. J. Ethnopharmacol. 110, 368\u2013373 (2007).","journal-title":"J. Ethnopharmacol."},{"key":"29393_CR47","first-page":"765","volume":"6","author":"JJ Wang","year":"2011","unstructured":"Wang, J. J. et al. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomedicine 6, 765\u201374 (2011).","journal-title":"Int. J. Nanomedicine"},{"key":"29393_CR48","first-page":"52","volume":"23","author":"S Wu","year":"1999","unstructured":"Wu, S. & Hopkins, W. Characteristics of d-\u03b1-tocopheryl PEG 1000 succinate for applications as an absorption enhancer in drug delivery systems. Pharm Technol. 23, 52\u201368 (1999).","journal-title":"Pharm Technol."},{"key":"29393_CR49","doi-asserted-by":"crossref","unstructured":"Davis, S. et al. \u03b1-Tocopherols Modify the Membrane Dipole Potential Leading to Modulation of Ligand Binding by P-glycoprotein. J Lipid Res (2015).","DOI":"10.1194\/jlr.M059519"},{"key":"29393_CR50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejps.2013.02.006","volume":"49","author":"Y Guo","year":"2013","unstructured":"Guo, Y., Luo, J., Tan, S., Otieno, B. O. & Zhang, Z. The applications of Vitamin e TPGS in drug delivery. Eur. J. Pharm. Sci. 49, 175\u2013186 (2013).","journal-title":"Eur. J. Pharm. Sci."},{"key":"29393_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cossms.2012.10.004","volume":"16","author":"B Sun","year":"2012","unstructured":"Sun, B. & Yeo, Y. Nanocrystals for the parenteral delivery of poorly water-soluble drugs. Curr. Opin. Solid State Mater. Sci. 16, 295\u2013301 (2012).","journal-title":"Curr. Opin. Solid State Mater. Sci."},{"key":"29393_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.colsurfb.2013.09.059","volume":"114","author":"J Hao","year":"2014","unstructured":"Hao, J. et al. Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery. Colloids Surfaces B Biointerfaces 114, 111\u2013120 (2014).","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"29393_CR53","first-page":"339","volume":"9","author":"JJ Escobar-Ch\u00e1vez","year":"2006","unstructured":"Escobar-Ch\u00e1vez, J. J. et al. Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. J. Pharm. Pharm. Sci. 9, 339\u201358 (2006).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"29393_CR54","first-page":"301","volume":"20","author":"GM Seigel","year":"2014","unstructured":"Seigel, G. M. Review: R28 retinal precursor cells: the first 20 years. Mol. Vis. 20, 301\u20136 (2014).","journal-title":"Mol. Vis."},{"key":"29393_CR55","doi-asserted-by":"publisher","unstructured":"Zhu, X. et al. Muscarinic activation attenuates abnormal processing of b-amyloid precursor protein induced by cobalt chloride-mimetic hypoxia in retinal ganglion cells, https:\/\/doi.org\/10.1016\/j.bbrc.2009.04.080 (2009).","DOI":"10.1016\/j.bbrc.2009.04.080"},{"key":"29393_CR56","first-page":"606","volume":"20","author":"M Aihara","year":"2014","unstructured":"Aihara, M., Chen, Y.-N., Uchida, S., Nakayama, M. & Araie, M. Hyperbaric pressure and increased susceptibility to glutamate toxicity in retinal ganglion cells in vitro. Mol. Vis. 20, 606\u201315 (2014).","journal-title":"Mol. Vis."},{"key":"29393_CR57","doi-asserted-by":"publisher","unstructured":"Davis, B. et al. Automatic quantitative analysis of experimental primary and secondary retinal neurodegeneration: implications for optic neuropathies. Cell Death Discov, https:\/\/doi.org\/10.1038\/cddiscovery.2016.31 (2016).","DOI":"10.1038\/cddiscovery.2016.31"},{"key":"29393_CR58","doi-asserted-by":"publisher","first-page":"20091","DOI":"10.3390\/molecules191220091","volume":"19","author":"KI Priyadarsini","year":"2014","unstructured":"Priyadarsini, K. I. The chemistry of curcumin: from extraction to therapeutic agent. Molecules 19, 20091\u2013112 (2014).","journal-title":"Molecules"},{"key":"29393_CR59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bpj.2011.05.033","volume":"101","author":"BM Davis","year":"2011","unstructured":"Davis, B. M., Richens, J. L. & O\u2019Shea, P. Label-free critical micelle concentration determination of bacterial quorum sensing molecules. Biophys. J. 101, 245\u201354 (2011).","journal-title":"Biophys. J."},{"key":"29393_CR60","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/BF01027775","volume":"180","author":"H T\u00f8nnesen","year":"1985","unstructured":"T\u00f8nnesen, H. & Karlsen, J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z. Lebensm. Unters. Forsch. 180, 402\u20134 (1985).","journal-title":"Kinetics of curcumin degradation in aqueous solution. Z. Lebensm. Unters. Forsch."},{"key":"29393_CR61","first-page":"855","volume":"15","author":"KN Engin","year":"2009","unstructured":"Engin, K. N. Alpha-tocopherol: looking beyond an antioxidant. Mol. Vis. 15, 855\u2013860 (2009).","journal-title":"Mol. Vis."},{"key":"29393_CR62","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1111\/j.1755-3768.2009.01632.x","volume":"88","author":"R Fato","year":"2010","unstructured":"Fato, R. et al. Coenzyme Q10 vitreous levels after administration of coenzyme Q10 eyedrops in patients undergoing vitrectomy. Acta Ophthalmol. 88, e150\u20131 (2010).","journal-title":"Acta Ophthalmol."},{"key":"29393_CR63","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.1021\/acs.jafc.5b00244","volume":"63","author":"C Schneider","year":"2015","unstructured":"Schneider, C., Gordon, O. N., Edwards, R. L. & Luis, P. B. Degradation of Curcumin: From Mechanism to Biological Implications. J. Agric. Food Chem. 63, 7606\u201314 (2015).","journal-title":"J. Agric. Food Chem."},{"key":"29393_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0378-5173(03)00299-0","volume":"261","author":"SL Raghavan","year":"2003","unstructured":"Raghavan, S. L., Schuessel, K., Davis, A. & Hadgraft, J. Formation and stabilisation of triclosan colloidal suspensions using supersaturated systems. Int. J. Pharm. 261, 153\u20138 (2003).","journal-title":"Int. J. Pharm."},{"key":"29393_CR65","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.2147\/IJN.S30428","volume":"7","author":"W Wang","year":"2012","unstructured":"Wang, W. et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int. J. Nanomedicine 7, 3667 (2012).","journal-title":"Int. J. Nanomedicine"},{"key":"29393_CR66","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ijpharm.2010.07.021","volume":"398","author":"RS Mulik","year":"2010","unstructured":"Mulik, R. S., M\u00f6nkk\u00f6nen, J., Juvonen, R. O., Mahadik, K. R. & Paradkar, A. R. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anticancer activity by induction of apoptosis. Int. J. Pharm. 398, 190\u2013203 (2010).","journal-title":"Int. J. Pharm."},{"key":"29393_CR67","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/qua.20469","volume":"102","author":"TM Kolev","year":"2005","unstructured":"Kolev, T. M., Velcheva, E. A., Stamboliyska, B. A. & Spiteller, M. DFT and experimental studies of the structure and vibrational spectra of curcumin. Int. J. Quantum Chem. 102, 1069\u20131079 (2005).","journal-title":"Int. J. Quantum Chem."},{"key":"29393_CR68","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.vibspec.2012.05.002","volume":"62","author":"PRK Mohan","year":"2012","unstructured":"Mohan, P. R. K., Sreelakshmi, G., Muraleedharan, C. V. & Joseph, R. Water soluble complexes of curcumin with cyclodextrins: Characterization by FT-Raman spectroscopy. Vib. Spectrosc. 62, 77\u201384 (2012).","journal-title":"Vib. Spectrosc."},{"key":"29393_CR69","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1442-9071.2006.01146.x","volume":"34","author":"RJ Casson","year":"2006","unstructured":"Casson, R. J. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin. Exp. Ophthalmol. 34, 54\u201363 (2006).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"29393_CR70","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.exer.2010.03.008","volume":"90","author":"NN Osborne","year":"2010","unstructured":"Osborne, N. N. Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma. Exp. Eye Res. 90, 750\u20137 (2010).","journal-title":"Exp. Eye Res."},{"key":"29393_CR71","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/toxsci\/kfj007","volume":"89","author":"Y Nakatsu","year":"2005","unstructured":"Nakatsu, Y. et al. Glutamate Excitotoxicity Is Involved in Cell Death Caused by Tributyltin in Cultured Rat Cortical Neurons. Toxicol. Sci. 89, 235\u2013242 (2005).","journal-title":"Toxicol. Sci."},{"key":"29393_CR72","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.freeradbiomed.2010.08.016","volume":"49","author":"Y Saito","year":"2010","unstructured":"Saito, Y. et al. Cytoprotective effects of vitamin E homologues against glutamate-induced cell death in immature primary cortical neuron cultures: Tocopherols and tocotrienols exert similar effects by antioxidant function. Free Radic. Biol. Med. 49, 1542\u20131549 (2010).","journal-title":"Free Radic. Biol. Med."},{"key":"29393_CR73","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12031-010-9343-z","volume":"42","author":"C Ergorul","year":"2010","unstructured":"Ergorul, C. et al. Hypoxia inducible factor-1\u03b1 (HIF-1\u03b1) and some HIF-1 target genes are elevated in experimental glaucoma. J. Mol. Neurosci. 42, 183\u201391 (2010).","journal-title":"J. Mol. Neurosci."},{"key":"29393_CR74","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/archopht.122.9.1348","volume":"122","author":"G Tezel","year":"2004","unstructured":"Tezel, G. et al. Hypoxia-Inducible Factor 1\u03b1 in the Glaucomatous Retina and OpticNerve Head. Arch. Ophthalmol. 122, 1348 (2004).","journal-title":"Arch. Ophthalmol."},{"key":"29393_CR75","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jscs.2010.02.005","volume":"14","author":"MS Al Okail","year":"2010","unstructured":"Al Okail, M. S. Cobalt chloride, a chemical inducer of hypoxia-inducible factor-1\u03b1 in U251 human glioblastoma cell line. J. Saudi Chem. Soc. 14, 197\u2013201 (2010).","journal-title":"J. Saudi Chem. Soc."},{"key":"29393_CR76","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3390\/ijms11052109","volume":"11","author":"S-Y Li","year":"2010","unstructured":"Li, S.-Y. & Lo, A. C. Y. Lutein protects RGC-5 cells against hypoxia and oxidative stress. Int. J. Mol. Sci. 11, 2109\u201317 (2010).","journal-title":"Int. J. Mol. Sci."},{"key":"29393_CR77","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3892\/mmr.2014.2551","volume":"10","author":"W DUAN","year":"2014","unstructured":"DUAN, W. et al. Curcumin inhibits hypoxia inducible factor-1\u03b1-induced epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma cells. Mol. Med. Rep. 10, 2505\u20132510 (2014).","journal-title":"Mol. Med. Rep."},{"key":"29393_CR78","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1530\/JOE-12-0207","volume":"214","author":"B Shan","year":"2012","unstructured":"Shan, B. et al. Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas. J. Endocrinol. 214, 389\u201398 (2012).","journal-title":"J. Endocrinol."},{"key":"29393_CR79","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.exer.2006.01.016","volume":"83","author":"O Arjamaa","year":"2006","unstructured":"Arjamaa, O. & Nikinmaa, M. Oxygen-dependent diseases in the retina: Role of hypoxia-inducible factors. Exp. Eye Res. 83, 473\u2013483 (2006).","journal-title":"Exp. Eye Res."},{"key":"29393_CR80","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1600-0420.2007.00885.x","volume":"85","author":"HH Sigurdsson","year":"2007","unstructured":"Sigurdsson, H. H., Konr\u00e1\u00f0sd\u00f3ttir, F., Loftsson, T. & Stef\u00e1nsson, E. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol. Scand. 85, 598\u2013602 (2007).","journal-title":"Acta Ophthalmol. Scand."},{"key":"29393_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2017.05.010","author":"BM Davis","year":"2017","unstructured":"Davis, B. M. et al. Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension. Mitochondrion., https:\/\/doi.org\/10.1016\/j.mito.2017.05.010 (2017).","journal-title":"Mitochondrion,"},{"key":"29393_CR82","first-page":"313","volume":"5","author":"P Neerati","year":"2013","unstructured":"Neerati, P., Sudhakar, Y. A. & Kanwar, J. R. Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ Cancerous Colon Perfusion Rat Model. J. Cancer Sci. Ther. 5, 313\u2013319 (2013).","journal-title":"J. Cancer Sci. Ther."},{"key":"29393_CR83","doi-asserted-by":"publisher","unstructured":"Guo, C. et al. Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation, https:\/\/doi.org\/10.1038\/srep12968 (2015).","DOI":"10.1038\/srep12968"},{"key":"29393_CR84","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1167\/iovs.08-3267","volume":"50","author":"FM Nadal-Nicol\u00e1s","year":"2009","unstructured":"Nadal-Nicol\u00e1s, F. M. et al. Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas. Invest. Ophthalmol. Vis. Sci. 50, 3860\u20138 (2009).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"29393_CR85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0074-7742(07)82022-8","volume":"82","author":"C Nucci","year":"2007","unstructured":"Nucci, C. et al. Retinal damage caused by high intraocular pressure\u2013induced transient ischemia is prevented by coenzyme Q10 in rat. Int. Rev. Neurobiol. 82, 397\u2013406 (2007).","journal-title":"Int. Rev. Neurobiol."},{"key":"29393_CR86","doi-asserted-by":"crossref","unstructured":"Kandarakis, A. et al. Efficacy of brimonidine in preventing intraocular pressure spikes following phacoemulsification in glaucoma patients. Eur. J. Ophthalmol. 20, 994\u20139.","DOI":"10.1177\/112067211002000619"},{"key":"29393_CR87","first-page":"61","volume":"274","author":"MF Cordeiro","year":"2017","unstructured":"Cordeiro, M. F. et al. Real-time imaging of single neuronal cell apoptosis in patients with glaucoma. Brain 274, 61\u20135 (2017).","journal-title":"Brain"},{"key":"29393_CR88","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/smll.201303433","volume":"10","author":"B Davis","year":"2014","unstructured":"Davis, B. et al. Topical Delivery of Avastin to the Posterior Segment of the Eye in vivo using Annexin A5-associated Liposomes. Small 10, 1575\u201384 (2014).","journal-title":"Small"},{"key":"29393_CR89","doi-asserted-by":"publisher","unstructured":"Jayaprakasha, G. K., Jagan Mohan Rao, K. & Sakariah*, K. K. Improved HPLC Method for the Determination of Curcumin, Demethoxycurcumin, and Bisdemethoxycurcumin, https:\/\/doi.org\/10.1021\/JF025506A (2002).","DOI":"10.1021\/JF025506A"},{"key":"29393_CR90","unstructured":"Lancaster, M. & Fields, R. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents. United States Patent: No 5501959 1\u201327 (1996)."},{"key":"29393_CR91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/exer.1996.0184","volume":"64","author":"JC Morrison","year":"1997","unstructured":"Morrison, J. C. et al. A rat model of chronic pressure-induced optic nerve damage. Exp. Eye Res. 64, 85\u201396 (1997).","journal-title":"Exp. Eye Res."},{"key":"29393_CR92","first-page":"3388","volume":"44","author":"H Levkovitch-Verbin","year":"2003","unstructured":"Levkovitch-Verbin, H. et al. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. IOVS 44, 3388\u201393 (2003).","journal-title":"IOVS"},{"key":"29393_CR93","doi-asserted-by":"publisher","first-page":"e49830","DOI":"10.1371\/journal.pone.0049830","volume":"7","author":"FM Nadal-Nicol\u00e1s","year":"2012","unstructured":"Nadal-Nicol\u00e1s, F. M. et al. Whole Number, Distribution and Co-Expression of Brn3 Transcription Factors in Retinal Ganglion Cells of Adult Albino and Pigmented Rats. PLoS One 7, e49830 (2012).","journal-title":"PLoS One"},{"key":"29393_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.174","volume":"7","author":"BM Davis","year":"2016","unstructured":"Davis, B. M. et al. Towards maximising information extraction from rodent models of ocular disease. Cell Death Dis. 7, e2270 (2016).","journal-title":"Cell Death Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29393-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T21:16:36Z","timestamp":1751750196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29393-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,23]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["29393"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-29393-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,23]]},"assertion":[{"value":"8 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.F.C., B.M.D. and S.S. have a patent application pertaining to the nanoparticle curcumin formulation described in this study. The authors declare no additional competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11066"}}